Official announcements from Yap Inc. — partnerships, awards, funding, and more.
Press Release
Yap signs a service agreement with Italy's Icarus — adapting an AI that takes the first call at medical institutions for Japan
Yap Inc. has signed a definitive service agreement, dated August 25, 2026, with Icarus S.r.l. (brand name: Icarus Technology), an Italian company providing a voice assistant in which AI answers calls to medical institutions. Following the memorandum of understanding signed on May 28, 2026, Yap now begins the research needed to adapt the service to Japanese healthcare settings. The name for the Japanese market is "Kyoko AI." No launch date in Japan has been decided at this time.
Yap Signs Memorandum of Understanding with Italy's Icarus S.r.l.
Yap Inc. has signed a Memorandum of Understanding (MoU) on a business partnership with Icarus S.r.l. (product brand: Icarus Technology), a company based in Sardinia, Italy. The MoU follows business development meetings in Tokyo, with the support of the Italian Trade Agency (ITA) and Regione Autonoma della Sardegna, and through SusHi Tech Tokyo, hosted by the Tokyo Metropolitan Government, and the venue of Tokyo Innovation Base. Icarus provides a multilingual AI voice assistant that automates patient phone reception for clinics; together the two companies aim to combine this with Yap's healthcare business and AI capabilities to expand in the Japanese market.
Yap Signs Partnership Agreement with Indonesian Digital Biobank Asa Ren
Yap Inc. has signed a business partnership agreement with Asa Ren, an Indonesian digital biobank company. Asa Ren operates Southeast Asia's first AI-powered digital biobank, integrating clinical and genomic data across diverse ethnic groups to advance personalized medicine and drug discovery. The two companies aim to expand awareness and adoption of Asa Ren's digital biobank.
Yap Signs Import Agreement with Bangladesh's UniMed UniHealth — First Bangladeshi Pharma to Enter Japan
Yap Inc. has signed an import agreement with UniMed UniHealth Pharmaceuticals Limited of Bangladesh. The agreement marks the first entry of a Bangladeshi pharmaceutical company into the Japanese market, beginning with Novotin, a biotin-based nutritional supplement.
Healthcare commentary shared by CEO Masaya Yamamoto on NewsPicks.
Platform
Filter by Tag
NewsPicksOctober 28, 2026
塩野義中間決算 ― 上期上振れの実態と下期リスクの読み方
Shionogi's interim results posted record highs for the first half, with revenue of ¥350.4 billion (+64.5% YoY) and operating profit of ¥115.2 billion (+55.8% YoY), prompting the company to raise its full-year operating profit guidance from ¥220 billion to ¥230 billion and its annual dividend from ¥76 to ¥86. Much of the growth, however, reflects businesses added through acquisitions, notably U.S. ALS drug RADICAVA at ¥50.9 billion and royalty income of ¥165.4 billion—roughly half of total revenue. The first-half beat against the ¥96 billion operating profit plan was also partly driven by R&D spending coming in ¥11.6 billion below budget. Subtracting first-half actuals from full-year guidance reveals that second-half operating profit and net profit attributable to the parent have each been trimmed, suggesting the full-year upgrade simply carries forward the first-half outperformance while the second-half outlook has actually turned more cautious. Two key variables to watch: whether acute respiratory infection drugs—including Xocova, which reached only 30% of its first-half plan—recover to the ¥25.3 billion second-half target as winter flu season unfolds, and whether the planned $2 billion acquisition of IntraBio (annual sales ~$68 million) can develop rare disease into a second pillar alongside RADICAVA.
The 'molecular Trojan horse' concept patented in 1989 has taken roughly 40 years to reach the final stage of clinical trials—a timeline that itself speaks to how difficult this approach truly is. The blood-brain barrier is a protective wall spanning the entire cerebral vasculature across some 640 kilometers, and the idea of exploiting receptor-mediated transport to ferry antibodies across it is technically impressive. Compared with conventional methods that required higher doses or intrathecal injection, delivering the drug in smaller amounts directly to the brain would be a meaningful advance. That said, what I most want to see is the safety profile. Existing amyloid antibody therapies have long struggled with ARIA—brain edema and microhemorrhages. Earlier-phase data suggest lower ARIA rates here, but because the antibody travels via receptor pathways, we need to watch for distinct adverse effects in non-brain tissues as well. On efficacy, the critical question is whether the degree of disease-progression slowing is large enough to be genuinely meaningful to patients and their families—something only the final results can confirm. In Japan, high-priced new drugs are also subject to cost-effectiveness-based price adjustments, so whether a scientific breakthrough actually translates into patient access will ultimately depend on how the post-approval regulatory framework is applied.
Research into the brain's waste-clearance mechanisms is genuinely fascinating. The study cited in the article—collecting cerebrospinal fluid every hour for 36 hours—revealed a clear diurnal rhythm in amyloid-beta concentrations, peaking in the afternoon and falling overnight, lending real weight to the hypothesis that the brain cleans house during sleep. That said, I want to pause here. While sleep deprivation studies have shown that amyloid-beta levels rise under intervention conditions, the leap from that finding to 'improving sleep prevents dementia' remains enormous, and framing it simply as 'good sleep protects the brain' skips too many steps. There is also a population that tends to be overlooked: family caregivers whose sleep is chronically cut short by nighttime care duties. Before we turn sleep into a matter of individual effort, we need a policy conversation about how to protect caregivers' sleep structurally.
Dementia & NeuroscienceSleep ResearchCaregiver Support & Policy
Applications of the gut microbiome are expanding well beyond digestion—into sports nutrition, healthy aging, weight management, and even the removal of PFAS and microplastics—and the sector is unmistakably becoming a broad-based industry, as illustrated by commercially launched strains like Synbio Tech's kimchi-derived TWK10. That said, the evidence underpinning the various claims sits at very different stages of maturity: findings from centenarian-derived strains remain at the mouse-study level, Akkermansia muciniphila's contribution to GLP-1 secretion is still described as 'suggestive,' and HMO-based improvements in elderly metabolic health are under 'investigation.' Because longevity and GLP-1 are among the most heavily funded buzzwords right now, preclinical results tend to migrate easily into product messaging. It is also worth remembering that the gut microbiome varies enormously between individuals, meaning the same strain will not necessarily work the same way for everyone. In Japan, functional labeling requires human-based evidence; the real test of trustworthiness in this field is whether sellers can clearly communicate which stage of evidence they are drawing on when overseas preclinical data flows into domestic product descriptions.
gut microbiomeevidence evaluationfunctional claims & regulation
Sugi HD's food sales have reached ¥206.7 billion, accounting for 30.2% of merchandise revenue. What stands out is the approach: rather than building a food division from scratch or acquiring a supermarket, the company has brought Trial's prepared foods and bento into select stores through a comprehensive partnership that involves no equity stake. At the pilot Sunami location, food's share of the product mix climbed to nearly 40%, with repeat visit rates and average spend both rising—a rational move to drive foot traffic while keeping capital outlay low. The flip side is worth watching, however. Trial stores hosting Sugi dispensing pharmacies are designed so customers can shop while waiting for prescriptions, but the more that wait time becomes shopping time, the less opportunity pharmacists have for meaningful conversation with patients. Looked at the other way, more frequent visits driven by food purchases also means more touchpoints between the pharmacy and the local community. The real question is whether those touchpoints can be converted into health consultations. Both companies say they plan to share purchase and behavioral data to develop total-healthcare services. If buying patterns for prepared foods can prompt conversations about salt reduction or blood sugar management, the case for drugstores handling food becomes clear. The metric to watch next is what indicator each company places after customer count.
At EASD 2026, a proposal emerged to classify pulmonary function decline as a 'fourth microvascular complication' of diabetes, alongside retinopathy, nephropathy, and neuropathy—conditions long managed under the principle of early, pre-symptomatic detection and intervention. If lung function deterioration also progresses silently, the same logic would seem to apply. That said, I am not convinced that spirometry should simply be added to the standard follow-up panel: the test is highly effort-dependent, maintaining reliable results across a busy diabetes clinic demands considerable staff time and training, and the evidence base for interventions that would actually improve prognosis after early detection remains thin. Before expanding screening, I would first want to assess how consistently the existing three-complication screens are being completed, and use that as a benchmark for gauging the priority of adding pulmonary assessment. Whether 'the fourth complication' takes hold as a clinical concept will ultimately depend on whether we can point to meaningful next steps once the finding is made.
Diabetic ComplicationsScreening PolicyPulmonary Function